1.2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease
Hye-Kyung JUNG ; Chung Hyun TAE ; Kyung Ho SONG ; Seung Joo KANG ; Jong Kyu PARK ; Eun Jeong GONG ; Jeong Eun SHIN ; Hyun Chul LIM ; Sang Kil LEE ; Da Hyun JUNG ; Yoon Jin CHOI ; Seung In SEO ; Joon Sung KIM ; Jung Min LEE ; Beom Jin KIM ; Sun Hyung KANG ; Chan Hyuk PARK ; Suck Chei CHOI ; Joong Goo KWON ; Kyung Sik PARK ; Moo In PARK ; Tae Hee LEE ; Seung Young KIM ; Young Sin CHO ; Han Hong LEE ; Kee Wook JUNG ; Do Hoon KIM ; Hee Seok MOON ; Mi-Young CHOI ; Kwang Jae LEE ;
Korean Journal of Medicine 2022;97(2):70-92
		                        		
		                        			
		                        			 Gastroesophageal reflux disease (GERD) is a condition in which gastric contents regurgitate into the esophagus or beyond, resulting in either troublesome symptoms or complications. GERD is heterogeneous in terms of varied manifestations, test findings, and treatment responsiveness. GERD diagnosis can be established with symptomatology, pathology, or physiology. Recently the Lyon consensus defined the “proven GERD” with concrete evidence for reflux, including advanced grade erosive esophagitis (Los Angeles classification grades C and or D esophagitis), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal esophageal acid exposure time > 6% on 24-hour ambulatory pH-impedance monitoring. However, some Asian researchers have different opinions on whether the same standards should be applied to the Asian population. The prevalence of GERD is increasing in Asia. The present evidence-based guidelines were developed using a systematic review and meta-analysis approach. In GERD with typical symptoms, a proton pump inhibitor test can be recommended as a sensitive, cost-effective, and practical test for GERD diagnosis. Based on a meta-analysis of 19 estimated acid-exposure time values in Asians, the reference range upper limit for esophageal acid exposure time was 3.2% (95% confidence interval 2.7-3.9%) in the Asian countries. Esophageal manometry and novel impedance measurements, including mucosal impedance and a post-reflux swallow-induced peristaltic wave, are promising in discrimination of GERD among different reflux phenotypes, thus increasing its diagnostic yield. We also propose a long-term strategy of evidence-based GERD treatment with proton pump inhibitors and other drugs. 
		                        		
		                        		
		                        		
		                        	
2.2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease
Hye-Kyung JUNG ; Chung Hyun TAE ; Kyung Ho SONG ; Seung Joo KANG ; Jong Kyu PARK ; Eun Jeong GONG ; Jeong Eun SHIN ; Hyun Chul LIM ; Sang Kil LEE ; Da Hyun JUNG ; Yoon Jin CHOI ; Seung In SEO ; Joon Sung KIM ; Jung Min LEE ; Beom Jin KIM ; Sun Hyung KANG ; Chan Hyuk PARK ; Suck Chei CHOI ; Joong Goo KWON ; Kyung Sik PARK ; Moo In PARK ; Tae Hee LEE ; Seung Young KIM ; Young Sin CHO ; Han Hong LEE ; Kee Wook JUNG ; Do Hoon KIM ; Hee Seok MOON ; Hirota MIWA ; Chien-Lin CHEN ; Sutep GONLACHANVIT ; Uday C GHOSHAL ; Justin C Y WU ; Kewin T H SIAH ; Xiaohua HOU ; Tadayuki OSHIMA ; Mi-Young CHOI ; Kwang Jae LEE ; The Korean Society of Neurogastroenterology and Motility
Journal of Neurogastroenterology and Motility 2021;27(4):453-481
		                        		
		                        			
		                        			Gastroesophageal reflux disease (GERD) is a condition in which gastric contents regurgitate into the esophagus or beyond, resulting in either troublesome symptoms or complications. GERD is heterogeneous in terms of varied manifestations, test findings, and treatment responsiveness. GERD diagnosis can be established with symptomatology, pathology, or physiology. Recently the Lyon consensus defined the “proven GERD” with concrete evidence for reflux, including advanced grade erosive esophagitis (Los Angeles classification grades C and or D esophagitis), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal esophageal acid exposure time > 6% on 24-hour ambulatory pH-impedance monitoring. However, some Asian researchers have different opinions on whether the same standards should be applied to the Asian population. The prevalence of GERD is increasing in Asia. The present evidence-based guidelines were developed using a systematic review and meta-analysis approach. In GERD with typical symptoms, a proton pump inhibitor test can be recommended as a sensitive, cost-effective, and practical test for GERD diagnosis.Based on a meta-analysis of 19 estimated acid-exposure time values in Asians, the reference range upper limit for esophageal acid exposure time was 3.2% (95% confidence interval, 2.7-3.9%) in the Asian countries. Esophageal manometry and novel impedance measurements, including mucosal impedance and a post-reflux swallow-induced peristaltic wave, are promising in discrimination of GERD among different reflux phenotypes, thus increasing its diagnostic yield. We also propose a long-term strategy of evidence-based GERD treatment with proton pump inhibitors and other drugs.
		                        		
		                        		
		                        		
		                        	
3.2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease
Hye-Kyung JUNG ; Chung Hyun TAE ; Kyung Ho SONG ; Seung Joo KANG ; Jong Kyu PARK ; Eun Jeong GONG ; Jeong Eun SHIN ; Hyun Chul LIM ; Sang Kil LEE ; Da Hyun JUNG ; Yoon Jin CHOI ; Seung In SEO ; Joon Sung KIM ; Jung Min LEE ; Beom Jin KIM ; Sun Hyung KANG ; Chan Hyuk PARK ; Suck Chei CHOI ; Joong Goo KWON ; Kyung Sik PARK ; Moo In PARK ; Tae Hee LEE ; Seung Young KIM ; Young Sin CHO ; Han Hong LEE ; Kee Wook JUNG ; Do Hoon KIM ; Hee Seok MOON ; Hirota MIWA ; Chien-Lin CHEN ; Sutep GONLACHANVIT ; Uday C GHOSHAL ; Justin C Y WU ; Kewin T H SIAH ; Xiaohua HOU ; Tadayuki OSHIMA ; Mi-Young CHOI ; Kwang Jae LEE ; The Korean Society of Neurogastroenterology and Motility
Journal of Neurogastroenterology and Motility 2021;27(4):453-481
		                        		
		                        			
		                        			Gastroesophageal reflux disease (GERD) is a condition in which gastric contents regurgitate into the esophagus or beyond, resulting in either troublesome symptoms or complications. GERD is heterogeneous in terms of varied manifestations, test findings, and treatment responsiveness. GERD diagnosis can be established with symptomatology, pathology, or physiology. Recently the Lyon consensus defined the “proven GERD” with concrete evidence for reflux, including advanced grade erosive esophagitis (Los Angeles classification grades C and or D esophagitis), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal esophageal acid exposure time > 6% on 24-hour ambulatory pH-impedance monitoring. However, some Asian researchers have different opinions on whether the same standards should be applied to the Asian population. The prevalence of GERD is increasing in Asia. The present evidence-based guidelines were developed using a systematic review and meta-analysis approach. In GERD with typical symptoms, a proton pump inhibitor test can be recommended as a sensitive, cost-effective, and practical test for GERD diagnosis.Based on a meta-analysis of 19 estimated acid-exposure time values in Asians, the reference range upper limit for esophageal acid exposure time was 3.2% (95% confidence interval, 2.7-3.9%) in the Asian countries. Esophageal manometry and novel impedance measurements, including mucosal impedance and a post-reflux swallow-induced peristaltic wave, are promising in discrimination of GERD among different reflux phenotypes, thus increasing its diagnostic yield. We also propose a long-term strategy of evidence-based GERD treatment with proton pump inhibitors and other drugs.
		                        		
		                        		
		                        		
		                        	
4.Long-term Breastfeeding in the Prevention of Allergic Rhinitis: Allergic Rhinitis Cohort Study for Kids (ARCO-Kids Study)
Doo Hee HAN ; Jae Min SHIN ; Seokyung AN ; Jong Seung KIM ; Dong Young KIM ; Sungji MOON ; Jung Soo KIM ; Joong Saeng CHO ; Si Whan KIM ; Young Hyo KIM ; Hwan Jung ROH ; Woo Sub SHIM ; Ki Sang RHA ; Sang Wook KIM ; Seung Sin LEE ; Dae Woo KIM ; Kyu Sup CHO ; Hyo Jin YIM ; Sue K PARK ; Chae Seo RHEE
Clinical and Experimental Otorhinolaryngology 2019;12(3):301-307
		                        		
		                        			
		                        			OBJECTIVES: There is a great deal of interest in the possibility that environmental factors may influence the risk of developing allergic rhinitis (AR) in early life. We investigated the simultaneous effects of mode of delivery and duration of breastfeeding on the development of AR in children. METHODS: Data from 1,374 children participating in the Allergic Rhinitis Cohort Study for kids (ARCO-kids study) was analyzed. All subjects were divided into AR or non-allergic rhinitis (NAR) groups. Data on environmental factors, mode of delivery and duration of breastfeeding were collected using a questionnaire. RESULTS: Compared with short-term breastfeeding (<6 months), long-term breastfeeding (≥12 months) was significantly associated with a lower prevalence of AR (adjusted odds ratio [aOR], 0.54; 95% confidence interval [CI], 0.34 to 0.88). Children in the AR group also had a higher cesarean delivery rate than those in the NAR group (39.1% vs. 32.8%, P=0.05). Regarding the combined effects of mode of delivery and duration of breastfeeding, long-term breastfeeding with a vaginal delivery strongly suppressed the development of AR, compared to short-term breastfeeding with a cesarean delivery (aOR, 0.47; 95% CI, 0.30 to 0.73). CONCLUSION: Long-term breastfeeding (≥12 months) and a vaginal delivery are associated with a lower risk of developing childhood AR.
		                        		
		                        		
		                        		
		                        			Breast Feeding
		                        			;
		                        		
		                        			Cesarean Section
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Delivery, Obstetric
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Odds Ratio
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Rhinitis
		                        			;
		                        		
		                        			Rhinitis, Allergic
		                        			
		                        		
		                        	
5.Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
Yu Mi KANG ; Chang Hee JUNG ; Seung Hwan LEE ; Sang Wook KIM ; Kee Ho SONG ; Sin Gon KIM ; Jae Hyeon KIM ; Young Min CHO ; Tae Sun PARK ; Bon Jeong KU ; Gwanpyo KOH ; Dol Mi KIM ; Byung Wan LEE ; Joong Yeol PARK
Diabetes & Metabolism Journal 2019;43(4):432-446
		                        		
		                        			
		                        			BACKGROUND: We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM). METHODS: This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia. RESULTS: The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. −0.9±6.0 kg, P=0.011). CONCLUSION: The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.
		                        		
		                        		
		                        		
		                        			Blood Glucose
		                        			;
		                        		
		                        			Body Weight
		                        			;
		                        		
		                        			Body Weight Changes
		                        			;
		                        		
		                        			Diabetes Mellitus, Type 2
		                        			;
		                        		
		                        			Fasting
		                        			;
		                        		
		                        			Hemoglobin A, Glycosylated
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypoglycemia
		                        			;
		                        		
		                        			Hypoglycemic Agents
		                        			;
		                        		
		                        			Insulin Glargine
		                        			;
		                        		
		                        			Insulin
		                        			;
		                        		
		                        			Metformin
		                        			;
		                        		
		                        			Morinda
		                        			
		                        		
		                        	
6.Successful Balloon Angioplasty with Low-pressure Balloon on Early Transplant Renal Artery Stenosis at Postoperative Day 7.
Doo Youp KIM ; Hyun Do JUNG ; Jin Ho LEE ; Han Sae KIM ; Dong Yeol LEE ; Joon Seok OH ; Seong Min KIM ; Yong Hun SIN ; Joong Kyung KIM ; Kill HUH ; Jong Hyun PARK ; Gyu Sik JUNG
The Journal of the Korean Society for Transplantation 2016;30(2):103-107
		                        		
		                        			
		                        			Transplant renal artery stenosis (TRAS) is an important cause of hypertension, allograft dysfunction, and graft loss. Patient and allograft survival rates are lower in patients with TRAS. Causes of TRAS include acute rejection, cytomegalovirus infection, calcineurin inhibitor toxicity, atherosclerosis of recipient, and/or donor. Technical problems due to surgery are a common cause of early TRAS. A 62-year-old male in end stage renal disease received kidney transplant surgery. There was 5/6 mismatch of human leukocyte antigen and the panel reactive antibody of patient was class I 0% and class II 0%. End to side anastomosis was done between the graft's renal artery and the patient's common iliac artery. His serum creatinine was measured at 6.4 mg/dL before transplantation but his serum creatinine level did not fall below 2.6 mg/dL at 5 days postoperative. His blood pressures was 160/90~180/100 mmHg. There was a significant TRAS (about 80% luminal narrowing) at the arterial anastomosis site on the renal magnetic resonance angiography. We performed percutaneous transluminal angioplasty (PTA) for the stenotic lesion. The balloon angioplasty was done with a 5 mm balloon and low pressure (8 mmHg, nominal pressure was 10 mmHg) at the stenotic lesion. The arterial pressure gradient was 8 mmHg (recipient's common iliac arterial pressure, 147/73 mmHg; poststenotic segmental renal arterial pressure, 139/70 mmHg) just before the balloon angioplasty. After PTA, the arterial pressure gradient became 3 mmHg (recipient's common iliac arterial pressure, 157/66 mmHg; poststenotic segmental renal arterial pressure, 154/65 mmHg). The arterial size and blood flow recovered to within normal range and serum creatinine level was normal after PTA. PTA using low pressure and a small balloon was safe and effective modality in treating early TRAS.
		                        		
		                        		
		                        		
		                        			Allografts
		                        			;
		                        		
		                        			Angioplasty
		                        			;
		                        		
		                        			Angioplasty, Balloon*
		                        			;
		                        		
		                        			Arterial Pressure
		                        			;
		                        		
		                        			Atherosclerosis
		                        			;
		                        		
		                        			Calcineurin
		                        			;
		                        		
		                        			Creatinine
		                        			;
		                        		
		                        			Cytomegalovirus Infections
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypertension
		                        			;
		                        		
		                        			Iliac Artery
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Kidney Failure, Chronic
		                        			;
		                        		
		                        			Kidney Transplantation
		                        			;
		                        		
		                        			Leukocytes
		                        			;
		                        		
		                        			Magnetic Resonance Angiography
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Phenobarbital
		                        			;
		                        		
		                        			Reference Values
		                        			;
		                        		
		                        			Renal Artery Obstruction*
		                        			;
		                        		
		                        			Renal Artery*
		                        			;
		                        		
		                        			Survival Rate
		                        			;
		                        		
		                        			Tissue Donors
		                        			;
		                        		
		                        			Transplants
		                        			
		                        		
		                        	
7.A Successful Case of a High Anti A/B Antibody Titer ABO Incompatible Kidney Transplantation Patient Who Received a Kidney from a Hepatitis B Carrier.
Jin Ho LEE ; Han Sae KIM ; Dong Yeol LEE ; Joon Seok OH ; Yong Hun SIN ; Joong Kyung KIM ; Jong Hyun PARK ; Kill HUH ; Jong In PARK
The Journal of the Korean Society for Transplantation 2016;30(4):184-189
		                        		
		                        			
		                        			Kidney transplantation (KTP) lowers the mortality and morbidity of patients with end-stage renal disease. Post-transplantation infection and antibody mediated rejection (AMR) are the most common complications. Hepatitis B surface antigen (HBsAg) positive carrier donors and high anti A/B antibody titer ABO incompatible KTP could lead to recipient hepatitis B virus (HBV) infection and AMR. Here, we report a case of successful KTP in a 41-year-old male with a high titer of ABO incompatible and HBsAg positive donor. He underwent seven rounds of plasmapheresis, low dose intravenous immunoglobulin and rituximab treatment to inhibit antibody production and remove antibodies from the serum, after which he was administered anti-viral agent for HBV prophylaxis. The recipient maintained successful allograft function for 6 months after transplantation; therefore, we report that desensitization and anti-viral treatment achieved successful outcome in a 1:512 anti A/B antibody titer ABO incompatible and hepatitis B carrier donor KTP.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Allografts
		                        			;
		                        		
		                        			Antibodies
		                        			;
		                        		
		                        			Antibody Formation
		                        			;
		                        		
		                        			Hepatitis B Surface Antigens
		                        			;
		                        		
		                        			Hepatitis B virus
		                        			;
		                        		
		                        			Hepatitis B*
		                        			;
		                        		
		                        			Hepatitis*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunoglobulins
		                        			;
		                        		
		                        			Kidney Failure, Chronic
		                        			;
		                        		
		                        			Kidney Transplantation*
		                        			;
		                        		
		                        			Kidney*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Plasmapheresis
		                        			;
		                        		
		                        			Rituximab
		                        			;
		                        		
		                        			Tissue Donors
		                        			
		                        		
		                        	
8.Incidences of Deep Vein Thrombosis and Pulmonary Embolism after Total Knee Arthroplasty Using a Mechanical Compression Device with and without Low-Molecular-Weight Heparin
Sin Hyung PARK ; Joong Hyeon AHN ; Yong Bok PARK ; Sun Geun LEE ; Soo Jae YIM
The Journal of Korean Knee Society 2016;28(3):213-218
		                        		
		                        			
		                        			PURPOSE: To investigate the incidence of thromboembolic events and complications related to bleeding after total knee arthroplasty (TKA) with a mechanical compression device alone or in combination with low-molecular-weight heparin (LMWH). MATERIALS AND METHODS: A total of 489 TKA patients (776 knees) were retrospectively reviewed for the incidence of thromboembolic events and complications related to bleeding. While 233 patients (354 knees) were treated with a mechanical compressive device without LMWH, 256 patients (422 knees) were treated with the mechanical compressive device along with LMWH. RESULTS: The incidences of deep vein thrombosis (DVT) and pulmonary embolism (PE) were 15 of 375 knees (4.0%) and 5 of 375 knees (1.3%), respectively, in the group that used only a mechanical compressive device, and 14 of 401 knees (3.4%) and 5 of 401 knees (1.2%), respectively, in the group that used the mechanical compressive device with LMWH. There was no significant difference between the two groups (p=0.125 and p=0.146, respectively). The postoperative hemovac drainage amount was 635±57 mL in the group with a mechanical compressive device only and 813±84 mL in the group with the device and LMWH; therefore, the amount of drainage was significantly greater in the latter group (p=0.013). CONCLUSIONS: Mechanical compression alone for prophylaxis against DVT and PE after TKA can be an attractive option in Korean patients.
		                        		
		                        		
		                        		
		                        			Arthroplasty
		                        			;
		                        		
		                        			Arthroplasty, Replacement, Knee
		                        			;
		                        		
		                        			Drainage
		                        			;
		                        		
		                        			Hemorrhage
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Knee
		                        			;
		                        		
		                        			Pulmonary Embolism
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Thromboembolism
		                        			;
		                        		
		                        			Venous Thrombosis
		                        			
		                        		
		                        	
9.Alterations of Colonic Contractility in an Interleukin-10 Knockout Mouse Model of Inflammatory Bowel Disease.
Jae Hyung PARK ; Joong Goo KWON ; Sun Joo KIM ; Dae Kyu SONG ; Seok Guen LEE ; Eun Su KIM ; Kwang Bum CHO ; Byung Ik JANG ; Dae Hwan KIM ; Jeong Im SIN ; Tae Wan KIM ; In Hwan SONG ; Kyung Sik PARK
Journal of Neurogastroenterology and Motility 2015;21(1):51-61
		                        		
		                        			
		                        			BACKGROUND/AIMS: Inflammatory bowel disease is commonly accompanied by colonic dysmotility and causes changes in intestinal smooth muscle contractility. In this study, colonic smooth muscle contractility in a chronic inflammatory condition was investigated using smooth muscle tissues prepared from interleukin-10 knockout (IL-10(-/-)) mice. METHODS: Prepared smooth muscle sections were placed in an organ bath system. Cholinergic and nitrergic neuronal responses were observed using carbachol and electrical field stimulation with L-NG-nitroarginine methyl ester (L-NAME). The expression of interstitial cells of Cajal (ICC) networks, muscarinic receptors, neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase (iNOS) was observed via immunofluorescent staining. RESULTS: The spontaneous contractility and expression of ICC networks in the proximal and distal colon was significantly decreased in IL-10(-/-) mice compared to IL-10(+/+) mice. The contractility in response to carbachol was significantly decreased in the proximal colon of IL-10(-/-) mice compared to IL-10(+/+) mice, but no significant difference was found in the distal colon. In addition, the expression of muscarinic receptor type 2 was reduced in the proximal colon of IL-10(-/-) mice. The nictric oxide-mediated relaxation after electrical field stimulation was significantly decreased in the proximal and distal colon of IL-10(-/-) mice. In inflamed colon, the expression of nNOS decreased, whereas the expression of iNOS increased. CONCLUSIONS: These results suggest that damage to the ICC network and NOS system in the proximal and distal colon, as well as damage to the smooth muscle cholinergic receptor in the proximal colon may play an important role in the dysmotility of the inflamed colon.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Baths
		                        			;
		                        		
		                        			Carbachol
		                        			;
		                        		
		                        			Colon*
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Interleukin-10*
		                        			;
		                        		
		                        			Interstitial Cells of Cajal
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Knockout*
		                        			;
		                        		
		                        			Muscle, Smooth
		                        			;
		                        		
		                        			Nitrergic Neurons
		                        			;
		                        		
		                        			Nitric Oxide Synthase Type I
		                        			;
		                        		
		                        			Nitric Oxide Synthase Type II
		                        			;
		                        		
		                        			Receptors, Muscarinic
		                        			;
		                        		
		                        			Relaxation
		                        			
		                        		
		                        	
10.A Case of Acute Antibody-Mediated Rejection Developed after Pretreatment with Rituximab and Plasma Exchange in a Highly-Sensitized Recipient with a Deceased Donor Kidney.
Seong Min KIM ; Joon Seok OH ; Yong Hun SIN ; Joong Kyung KIM ; Jong In PARK ; Kill HUH ; Yong Jin KIM
The Journal of the Korean Society for Transplantation 2012;26(2):125-130
		                        		
		                        			
		                        			Acute antibody-mediated rejection is the major cause of graft failure in the early stage of kidney transplantation. Preoperative treatment and early diagnosis of acute rejection is very important to prevent graft loss in sensitized patients. High panel reactive antibody (PRA) means a likelihood of acute rejection, and the recipient of high PRA needs adequate pretreatment for kidney transplantation. However, there is not sufficient time and chances for desensitization in deceased kidney transplants. We report a successful renal transplant outcome in a 47-year-old-woman with high PRA levels (Class I 97.5%, Class II 36.7%). The cross match was negative on the CDC (ELISA) and flowcytometric methods. Plasma exchange was performed on the recipient before transplantation (fresh frozen plasma replacement, 1.3 plasma volume) and immediately after plasma exchange she was given 200 mg of rituximab. She received basiliximab and methyl prednisolone induction therapy and was maintained on steroids, mycophenolate mofetil, and tacrolimus. Graft function was normal immediately after transplantation, but decreased urinary output and elevated serum creatinine was noted on POD 5. On POD 6, a graft biopsy revealed acute cellular rejection (Type IIa) and antibody-mediated rejection (Type II). On 9~13 days after transplantation, additional plasma exchange was performed every other day, and steroid pulse therapy was performed 3 times. After normalization of urinary output and serum creatinine, the patient was discharged and is being followed up on. In conclusion, immunologically careful preparation and pretransplant treatment may be needed on the negative cross match in cadaveric kidney recipients with high levels of PRA.
		                        		
		                        		
		                        		
		                        			Antibodies, Monoclonal
		                        			;
		                        		
		                        			Antibodies, Monoclonal, Murine-Derived
		                        			;
		                        		
		                        			Biopsy
		                        			;
		                        		
		                        			Cadaver
		                        			;
		                        		
		                        			Centers for Disease Control and Prevention (U.S.)
		                        			;
		                        		
		                        			Creatinine
		                        			;
		                        		
		                        			Early Diagnosis
		                        			;
		                        		
		                        			Graft Rejection
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunization
		                        			;
		                        		
		                        			Kidney
		                        			;
		                        		
		                        			Kidney Transplantation
		                        			;
		                        		
		                        			Mycophenolic Acid
		                        			;
		                        		
		                        			Plasma
		                        			;
		                        		
		                        			Plasma Exchange
		                        			;
		                        		
		                        			Prednisolone
		                        			;
		                        		
		                        			Recombinant Fusion Proteins
		                        			;
		                        		
		                        			Rejection (Psychology)
		                        			;
		                        		
		                        			Rituximab
		                        			;
		                        		
		                        			Steroids
		                        			;
		                        		
		                        			Tacrolimus
		                        			;
		                        		
		                        			Tissue Donors
		                        			;
		                        		
		                        			Transplants
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail